NAVER Corp. 035420
KRX · South Korea · Technology Services
KRW 191,200.00-2,500.00 (-1.29%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
NAVER D2SF, NAVER's inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed's $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions. NAVER D2SF's investment reflects ImpriMed's commercial and clinical experience in the U.S. healthc
Krafton's planned investment in India is set to surpass $500 million with its latest commitment.
NAVER D2SF, the corporate venture capital arm of NAVER, has made a new investment in F4GE (CEO, Hyukhyun Kwon), a defense and manufacturing infrastructure startup. F4GE is building infrastructure that integrates Korea's fragmented core manufacturing factories into a unified manufacturing network and connects them with global defense and advanced hardware companies. NAVER D2SF decided to invest in the team based on its ability to identify new business opportunities for Korea's manufacturing capab
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.